common.study.topics.clinical

Recombinant Influenza Vaccination in U.S. Nursing Homes

common.study.values.description

Recombinant Influenza Vaccination in U.S. Nursing Homes

Based on recent evidence on the mutation of the A/H3N2 strain in egg-grown vaccine, the investigators will study the quadrivalent recombinant influenza vaccine (RIV4, Flublok) compared to the standard dose quadrivalent vaccine (IV4) in a cohort of long-stay NH residents with a primary endpoint of all-cause respiratory-related hospitalization.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Biological - Recombinant Influenza Vaccine

Nursing home residents and staff 18 years and older are allocated to receive quadrivalent recombinant influenza vaccine.

Biological - Standard Dose Quadrivalent Influenza Vaccine

Nursing home residents and staff 18 years and older are allocated to receive standard dose quadrivalent influenza vaccine

participant.views.study.view.additional

participant.views.study.view.scientific-title

Comparative Effectiveness of Recombinant Versus Standard Dose Quadrivalent Influenza Vaccine in U.S. Nursing Homes

common.study.values.clinical-trial-id

NCT03965195

participant.views.study.view.id

dJ6xKd